Advertisement

Topics

CIBMTR announces collaboration with Kite to track long-term outcomes data for YESCARTA

20:00 EDT 16 May 2018 | AAAS

(Be The Match) A new collaboration focused on tracking long-term outcomes of patients treated with chimeric antigen receptor T cell (CAR T) therapies is formed between the CIBMTR® (Center for International Blood and Marrow Transplant Research), and Kite, a Gilead Company. CIBMTR is an organization that collaborates with the global scientific community to advance hematopoietic cell transplantation (HCT) and cellular therapy worldwide. Under the terms of the agreement, CIBMTR will collect and analyze long-term safety and efficacy data for YESCARTA® in a commercial setting.

Original Article: CIBMTR announces collaboration with Kite to track long-term outcomes data for YESCARTA

NEXT ARTICLE

More From BioPortfolio on "CIBMTR announces collaboration with Kite to track long-term outcomes data for YESCARTA"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Transplantation
Organ transplantation is the moving of an organ from one body to another or from a donor site to another location on the patient's own body, for the purpose of replacing the recipient's damaged or absent organ. The emerging field of regenerative ...